Talon Private Wealth LLC Grows Stake in Tenet Healthcare Corporation $THC

Talon Private Wealth LLC boosted its stake in shares of Tenet Healthcare Corporation (NYSE:THC) by 35.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,097 shares of the company’s stock after acquiring an additional 6,044 shares during the quarter. Talon Private Wealth LLC’s holdings in Tenet Healthcare were worth $4,321,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of THC. Triumph Capital Management purchased a new stake in shares of Tenet Healthcare in the third quarter valued at $25,000. Elyxium Wealth LLC bought a new position in Tenet Healthcare during the 4th quarter valued at about $29,000. Canada Pension Plan Investment Board purchased a new stake in Tenet Healthcare in the 2nd quarter worth about $35,000. Trust Co. of Vermont bought a new stake in Tenet Healthcare in the second quarter worth about $37,000. Finally, Meeder Asset Management Inc. boosted its position in shares of Tenet Healthcare by 146.2% during the fourth quarter. Meeder Asset Management Inc. now owns 192 shares of the company’s stock valued at $38,000 after buying an additional 114 shares during the period. Hedge funds and other institutional investors own 95.44% of the company’s stock.

Insider Buying and Selling

In other Tenet Healthcare news, Director Christopher Lynch sold 3,837 shares of the company’s stock in a transaction on Monday, July 27th. The stock was sold at an average price of $243.44, for a total transaction of $934,079.28. Following the completion of the sale, the director owned 9,568 shares in the company, valued at $2,329,233.92. This represents a 28.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Saumya Sutaria sold 50,000 shares of Tenet Healthcare stock in a transaction on Monday, August 24th. The shares were sold at an average price of $278.71, for a total value of $13,935,500.00. Following the completion of the transaction, the chief executive officer owned 483,564 shares in the company, valued at $134,774,122.44. This represents a 9.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 109,189 shares of company stock valued at $29,264,109 over the last ninety days. Company insiders own 0.97% of the company’s stock.

Tenet Healthcare Stock Down 0.2%

Shares of THC traded down $0.45 during midday trading on Friday, reaching $263.01. 588,085 shares of the stock were exchanged, compared to its average volume of 1,197,213. The company has a current ratio of 1.41, a quick ratio of 1.35 and a debt-to-equity ratio of 2.00. The company’s 50 day moving average is $243.84 and its two-hundred day moving average is $212.04. The company has a market capitalization of $21.18 billion, a P/E ratio of 10.14, a PEG ratio of 1.03 and a beta of 1.23. Tenet Healthcare Corporation has a 52 week low of $157.58 and a 52 week high of $283.05.

Tenet Healthcare (NYSE:THC) last issued its earnings results on Thursday, July 23rd. The company reported $6.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.26 by $1.86. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The company had revenue of $6.04 billion for the quarter, compared to analysts’ expectations of $5.43 billion. During the same period in the prior year, the business earned $4.02 EPS. The firm’s quarterly revenue was up 6.8% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. On average, sell-side analysts anticipate that Tenet Healthcare Corporation will post 21.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. The Goldman Sachs Group reissued a “buy” rating and set a $305.00 price target on shares of Tenet Healthcare in a research note on Tuesday, July 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Tenet Healthcare in a research note on Monday, July 27th. Stephens reissued an “overweight” rating and set a $285.00 target price on shares of Tenet Healthcare in a research note on Monday, July 27th. UBS Group raised their price target on shares of Tenet Healthcare from $288.00 to $308.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. Finally, Weiss Ratings upgraded shares of Tenet Healthcare from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $275.53.

Tenet Healthcare Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company that owns and operates acute care hospitals and other healthcare facilities in the United States. Its hospitals provide services including emergency care, surgery, cardiovascular care, orthopedics, oncology, women’s health and other inpatient and outpatient treatments.

Through its ambulatory business, United Surgical Partners International, Tenet operates and manages ambulatory surgery centers and other outpatient facilities.